查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1815753

2025年双胍类药物全球市场报告

Biguanides Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年双胍类药物市场将稳定成长，到2029年将达到58.1亿美元，复合年增长率为3.2%。预测期内成长的主要驱动力包括联合治疗的日益普及、药物输送技术的进步、研发投入的不断增加、医疗保健支出的不断增长以及在卵巢综合征(PCOS)治疗中的应用不断扩展。预测期内的主要趋势包括对缓释性开发的日益关注、对联合疗法的日益偏好、在肿瘤学中的应用不断扩展，以及疗效和安全性均有所提升的新型双胍类药物的出现。

我们预测未来五年该市场将成长3.2%，较我们先前对该市场的预测略有收缩0.5%。这一下降主要源自于美国与其他国家之间关税的影响。贸易摩擦可能导致中国和以色列生产的二甲双胍製剂价格上涨，从而扰乱美国的内分泌学实践，导致2型糖尿病管理延迟，并增加3400万美国患者的代谢紊乱治疗费用。由于互惠关税以及贸易紧张局势和限制加剧对全球经济和贸易的负面影响，贸易摩擦的影响也将更加广泛。

糖尿病盛行率的上升预计将在短期内推动双胍类药物市场的扩张。糖尿病是一种慢性代谢性疾病，其特征是胰岛素分泌不足导致血糖值升高。由于生活方式改变、人口老化、遗传因素、诊断方法的改进和环境影响等多种因素，糖尿病的发生率正在上升。二甲双胍等双胍类药物可透过提高胰岛素敏感性、抑制肝醣生成和降低第 2 型糖尿病患者的血糖值来帮助控製糖尿病。例如，根据英国政府健康改善与差异办公室的数据，从 2022 年 3 月到 2023 年 3 月，接受针对 1 型和 2 型糖尿病的所有八个建议护理步骤的人数比例都显着增加。此外，达到 HbA1c 目标值的人数比例达到了创纪录的 37.9%。因此，糖尿病盛行率的上升正在推动双胍类药物市场的成长。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球双胍类药物：PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 最终用途产业分析
  • 全球双胍类市场：成长率分析
  • 全球双胍类市场表现：规模与成长，2019-2024
  • 全球双胍类市场预测：2024-2029年及2034年规模与成长
  • 全球双胍类药物：总潜在市场（TAM）

第六章 市场细分

  • 全球双胍类药物市场：依类型、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 二甲双胍
  • 苯乙双胍
  • 其他类型
  • 全球双胍类药物市场（按剂型、性能和预测），2019-2024 年、2024-2029 年、2034 年
  • 药片
  • 口服溶液
  • 全球双胍类市场（按配方、性能和预测），2019-2024 年、2024-2029 年、2034 年
  • 即时发布
  • 延长释放
  • 全球双胍类市场：按分销管道、实际情况和预测，2019-2024 年、2024-2029 年、2034 年
  • 医院药房
  • 零售药局
  • 网路药局
  • 全球双胍类药物市场：依二甲双胍类型细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 速释二甲双胍
  • 缓释性二甲双胍
  • 全球双胍类药物市场：依苯乙双胍类型细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 盐酸苯乙双胍
  • 全球双胍类药物市场：按类型、实际和预测细分，2019-2024 年、2024-2029 年、2034 年
  • 丁福明
  • 同时使用二甲双胍

第七章 区域和国家分析

  • 全球双胍类市场：依地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球双胍类市场：依国家、表现及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 双胍类市场：竞争格局
  • 双胍类市场：公司简介
    • Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi-Aventis LLC Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • AstraZeneca plc
  • Novartis AG
  • GlaxoSmithKline plc
  • Takeda Pharmaceuticals Company Limited
  • Novo Nordisk A/S
  • Viatris Inc.
  • Daiichi Sankyo Company Limited
  • Wanbury Ltd
  • Boehringer Ingelheim International GmbH
  • Intas Pharmaceuticals Ltd.
  • Aurobindo Pharma Ltd.
  • Cipla Ltd
  • Shionogi & Co. Ltd.
  • Dr. Reddy's Laboratories
  • Lupin Limited

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

  • 2029 年双胍类药物市场：提供新机会的国家
  • 2029 年双胍类药物市场：细分领域带来新机会
  • 双胍类药物市场 2029：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r29585u

Biguanides comprise a class of medications primarily employed in the treatment of type 2 diabetes. They aid in lowering blood sugar levels by reducing the liver's production of sugar and enhancing the body's responsiveness to insulin. Additionally, these medications find utility in treating polycystic ovary syndrome (PCOS) and other metabolic disorders.

The primary types of biguanides include metformin, phenformin, and others. Metformin stands out as a widely utilized biguanide medication for type 2 diabetes management, effectively lowering blood sugar levels. Available in various dosage forms such as tablets and oral solutions, metformin is offered in different formulations including immediate-release and extended-release variants. These medications are distributed through a variety of channels including hospital pharmacies, retail pharmacies, and online platforms.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The biguanides market research report is one of a series of new reports from The Business Research Company that provides biguanides market statistics, including biguanides industry global market size, regional shares, competitors with a biguanides market share, detailed biguanides market segments, market trends and opportunities, and any further data you may need to thrive in the biguanides industry. This biguanides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biguanides market size has grown steadily in recent years. It will grow from $4.96 billion in 2024 to $5.11 billion in 2025 at a compound annual growth rate (CAGR) of 3.1%. The growth in the historic period can be attributed to a rise in demand for oral hypoglycemic drugs, growth in the geriatric population, rise in obesity rates, and increased awareness about diabetes management.

The biguanides market size is expected to see steady growth in the next few years. It will grow to $5.81 billion in 2029 at a compound annual growth rate (CAGR) of 3.2%. The growth in the forecast period can be attributed to the growing adoption of combination therapies, advancements in drug delivery technologies, increasing investment in research and development, rising healthcare expenditure, and expanding applications in the treatment of polycystic ovary syndrome. Major trends in the forecast period include increasing focus on developing extended-release formulations, growing preference for fixed-dose combination therapies, expanding applications in oncology, and the emergence of novel biguanides with improved efficacy and safety profiles.

The forecast of 3.2% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. endocrinology practices by inflating prices of metformin formulations manufactured in China and Israel, resulting in delayed type 2 diabetes management and higher metabolic disorder treatment costs for 34 million American patients. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increase in diabetes cases is anticipated to drive the expansion of the biguanides market in the foreseeable future. Diabetes, a chronic metabolic disorder characterized by elevated blood sugar levels due to insufficient insulin production, is on the rise due to various factors such as lifestyle shifts, population aging, genetic factors, improved diagnostic methods, and environmental influences. Biguanides such as metformin help manage diabetes by enhancing insulin sensitivity, reducing liver glucose production, and lowering blood sugar levels in individuals with type 2 diabetes. For example, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals receiving all eight recommended care processes for type 1 and type 2 diabetes increased significantly. Additionally, the percentage of individuals achieving target HbA1c levels reached a record high of 37.9%. Therefore, the increasing prevalence of diabetes is propelling the growth of the biguanides market.

Leading companies in the biguanides market are concentrating on developing advanced solutions such as extended-release formulations to enhance patient compliance, improve therapeutic effectiveness, and minimize side effects. Extended-release biguanides slowly release their active ingredients, ensuring consistent blood levels and better glycemic control for diabetes patients, thereby enhancing treatment adherence. For instance, in August 2023, Dr. Reddy's Laboratories, an India-based biotechnology company, introduced saxagliptin and metformin hydrochloride extended-release drugs, a generic version of KOMBIGLYZE XR approved by the US Food and Drug Administration (USFDA). This combination medication, consisting of saxagliptin, a DPP-4 inhibitor, and metformin, a biguanide, aims to improve glycemic control in adults with type 2 diabetes mellitus when used in conjunction with diet and exercise. The extended-release formulation enhances patient adherence and efficacy.

In August 2023, Lupin, an India-based biopharmaceutical company, acquired diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim for an undisclosed sum. This acquisition enables Lupin to expand its product portfolio and strengthen its position in the anti-diabetes segment, ensuring broader access to medication for patients. Boehringer Ingelheim, a Germany-based biopharmaceutical company, is renowned for its research, development, and production of therapies for both human and veterinary medicine.

Major companies operating in the biguanides market are Cardinal Health Inc., Pfizer Inc., Merck And Co Inc, Bayer AG, Sanofi-Aventis LLC, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceuticals Company Limited, Novo Nordisk A/S, Viatris Inc., Daiichi Sankyo Company Limited, Wanbury Ltd, Boehringer Ingelheim International GmbH, Intas Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Cipla Ltd, Shionogi & Co Ltd, Dr. Reddy's Laboratories, Lupin Limited, Zydus Lifesciences Limited, Apotex Inc, Torrent Pharmaceuticals Limited, Panacea Biotech Ltd., Auro Laboratories Limited

Asia-Pacific was the largest region in the biguanides market in 2024. Middle East And Africa is expected to be the fastest-growing region in the forecast period. The regions covered in the biguanides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the biguanides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The biguanides market consists of sales of Chlorhexidine, Polyhexanide, Proguanil, and Buformin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biguanides Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biguanides market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biguanides ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biguanides market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Metformin; Phenformin; Other Types
  • 2) By Dosage Form: Tablets; Oral Solutions
  • 3) By Formulation: Immediate Release; Extended Release
  • 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Subsegments:
  • 1) By Metformin: Immediate-Release Metformin; Extended-Release Metformin
  • 2) By Phenformin: Phenformin Hydrochloride
  • 3) By Other Types: Buformin; Metformin Combinations
  • Companies Mentioned: Cardinal Health Inc.; Pfizer Inc.; Merck And Co Inc; Bayer AG; Sanofi-Aventis LLC; AstraZeneca plc; Novartis AG; GlaxoSmithKline plc; Takeda Pharmaceuticals Company Limited; Novo Nordisk A/S; Viatris Inc.; Daiichi Sankyo Company Limited; Wanbury Ltd; Boehringer Ingelheim International GmbH; Intas Pharmaceuticals Ltd.; Aurobindo Pharma Ltd.; Cipla Ltd; Shionogi & Co Ltd; Dr. Reddy's Laboratories; Lupin Limited; Zydus Lifesciences Limited; Apotex Inc; Torrent Pharmaceuticals Limited; Panacea Biotech Ltd.; Auro Laboratories Limited
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biguanides Market Characteristics

3. Biguanides Market Trends And Strategies

4. Biguanides Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Biguanides Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Biguanides PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Biguanides Market Growth Rate Analysis
  • 5.4. Global Biguanides Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Biguanides Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Biguanides Total Addressable Market (TAM)

6. Biguanides Market Segmentation

  • 6.1. Global Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Metformin
  • Phenformin
  • Other Types
  • 6.2. Global Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Tablets
  • Oral Solutions
  • 6.3. Global Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immediate Release
  • Extended Release
  • 6.4. Global Biguanides Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.5. Global Biguanides Market, Sub-Segmentation Of Metformin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immediate-Release Metformin
  • Extended-Release Metformin
  • 6.6. Global Biguanides Market, Sub-Segmentation Of Phenformin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Phenformin Hydrochloride
  • 6.7. Global Biguanides Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Buformin
  • Metformin Combinations

7. Biguanides Market Regional And Country Analysis

  • 7.1. Global Biguanides Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Biguanides Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biguanides Market

  • 8.1. Asia-Pacific Biguanides Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biguanides Market

  • 9.1. China Biguanides Market Overview
  • 9.2. China Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biguanides Market

  • 10.1. India Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biguanides Market

  • 11.1. Japan Biguanides Market Overview
  • 11.2. Japan Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biguanides Market

  • 12.1. Australia Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biguanides Market

  • 13.1. Indonesia Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biguanides Market

  • 14.1. South Korea Biguanides Market Overview
  • 14.2. South Korea Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biguanides Market

  • 15.1. Western Europe Biguanides Market Overview
  • 15.2. Western Europe Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biguanides Market

  • 16.1. UK Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biguanides Market

  • 17.1. Germany Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biguanides Market

  • 18.1. France Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biguanides Market

  • 19.1. Italy Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biguanides Market

  • 20.1. Spain Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biguanides Market

  • 21.1. Eastern Europe Biguanides Market Overview
  • 21.2. Eastern Europe Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biguanides Market

  • 22.1. Russia Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biguanides Market

  • 23.1. North America Biguanides Market Overview
  • 23.2. North America Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biguanides Market

  • 24.1. USA Biguanides Market Overview
  • 24.2. USA Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biguanides Market

  • 25.1. Canada Biguanides Market Overview
  • 25.2. Canada Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biguanides Market

  • 26.1. South America Biguanides Market Overview
  • 26.2. South America Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biguanides Market

  • 27.1. Brazil Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biguanides Market

  • 28.1. Middle East Biguanides Market Overview
  • 28.2. Middle East Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biguanides Market

  • 29.1. Africa Biguanides Market Overview
  • 29.2. Africa Biguanides Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Biguanides Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Biguanides Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biguanides Market Competitive Landscape And Company Profiles

  • 30.1. Biguanides Market Competitive Landscape
  • 30.2. Biguanides Market Company Profiles
    • 30.2.1. Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Sanofi-Aventis LLC Overview, Products and Services, Strategy and Financial Analysis

31. Biguanides Market Other Major And Innovative Companies

  • 31.1. AstraZeneca plc
  • 31.2. Novartis AG
  • 31.3. GlaxoSmithKline plc
  • 31.4. Takeda Pharmaceuticals Company Limited
  • 31.5. Novo Nordisk A/S
  • 31.6. Viatris Inc.
  • 31.7. Daiichi Sankyo Company Limited
  • 31.8. Wanbury Ltd
  • 31.9. Boehringer Ingelheim International GmbH
  • 31.10. Intas Pharmaceuticals Ltd.
  • 31.11. Aurobindo Pharma Ltd.
  • 31.12. Cipla Ltd
  • 31.13. Shionogi & Co. Ltd.
  • 31.14. Dr. Reddy's Laboratories
  • 31.15. Lupin Limited

32. Global Biguanides Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biguanides Market

34. Recent Developments In The Biguanides Market

35. Biguanides Market High Potential Countries, Segments and Strategies

  • 35.1 Biguanides Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Biguanides Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Biguanides Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer